Objective      To evaluate the clinica1 efficacy of donor-derived cytokine induced killer cells (CIK) after allogeneic stem cell transplantation (allo-HSCT) in the treatment of patients with refractory/relapsed hematologic neoplasms.       Methods      Eleven refractory/relapsed patients

including acute myelogenous leukemia (AML) (n=3)

acute lymphoblastic leuk

emia (ALL) (n=1)

chronic myelomonocytic leukemia (CML) (n=2)

  multiple myeloma (MM) (n=1) and non-Hodgkin lymphoma (NHL) (n=4)

were enrolled in this retrospective analysis. All the patients accepted the infusions of donor-derived CIK after allo-HSCT.       Results      Hematopoietic reconstitution was achieved in 11 patients. The median number of CIK infusions was 4 (range 2 to 7) and the median number of total CIK cells was 11.9×10

6

/kg (range 5.8 to 86.5). The primary disease achieved complete responses in all the patients. Four patient relapsed again after allo-HSCT and CIK cell infusion. However

3 patients of them achieved complete responses after stopping immunosuppressive therapy and accepting the infusions of CIK. Among the 4 died patients

2 died of idiopathic pulmonary syndrome

and 2 of severe infection. The median time of follow-up was 9 months (ranging from 2 to 53 months). During the follow-up period

7 patients had always stayed CCR except 1 patient relapsed in molecule biology.       Conclusion      Allo-HSCT combined CIK adaptive immunotherapy is an effective therapy with little side effect for  minimal residual disease (MRD) clearance for malignancy

and it is worth of doing a multi-center controlled clinical trail study for its efficiency.